Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19.
Publication
, Journal Article
Ashraf, S; Ashraf, N
Published in: JAMA
May 16, 2023
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
May 16, 2023
Volume
329
Issue
19
Start / End Page
1702
Location
United States
Related Subject Headings
- Time Factors
- Recovery of Function
- Humans
- General & Internal Medicine
- Fluvoxamine
- Double-Blind Method
- COVID-19 Drug Treatment
- COVID-19
- Antiviral Agents
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ashraf, S., & Ashraf, N. (2023). Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA, 329(19), 1702. https://doi.org/10.1001/jama.2023.5061
Ashraf, Sahar, and Nauman Ashraf. “Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19.” JAMA 329, no. 19 (May 16, 2023): 1702. https://doi.org/10.1001/jama.2023.5061.
Ashraf S, Ashraf N. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. 2023 May 16;329(19):1702.
Ashraf, Sahar, and Nauman Ashraf. “Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19.” JAMA, vol. 329, no. 19, May 2023, p. 1702. Pubmed, doi:10.1001/jama.2023.5061.
Ashraf S, Ashraf N. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. 2023 May 16;329(19):1702.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
May 16, 2023
Volume
329
Issue
19
Start / End Page
1702
Location
United States
Related Subject Headings
- Time Factors
- Recovery of Function
- Humans
- General & Internal Medicine
- Fluvoxamine
- Double-Blind Method
- COVID-19 Drug Treatment
- COVID-19
- Antiviral Agents
- 42 Health sciences